Pterostilbene Protects against Osteoarthritis through NLRP3 Inflammasome Inactivation and Improves Gut Microbiota as Evidenced by In Vivo and In Vitro Studies

Osteoarthritis (OA) is a persistent inflammatory disease, and long-term clinical treatment often leads to side effects. In this study, we evaluated pterostilbene (PT), a natural anti-inflammatory substance, for its protective effects and safety during prolonged use on OA. Results showed that PT alleviated the loss of chondrocytes and widened the narrow joint space in an octacalcium phosphate (OCP)-induced OA mouse model (n = 3). In vitro experiments demonstrate that PT reduced NLRP3 inflammation activation (relative protein expression: C: 1 +/- 0.09, lipopolysaccharide (LPS): 1.14 +/- 0.07, PT: 0.91 +/- 0.07, LPS + PT: 0.68 +/- 0.04) and the release of inflammatory cytokines through NF-kappa B signaling inactivation (relative protein expression: C: 1 +/- 0.03, LPS: 3.49 +/- 0.02, PT: 0.66 +/- 0.08, LPS + PT: 2.78 +/- 0.05), ultimately preventing cartilage catabolism. Interestingly, PT also altered gut microbiota by reducing inflammation-associated flora and increasing the abundance of healthy bacteria in OA groups. Collectively, these results suggest that the PT can be considered as a protective strategy for OA.